No trading signal. The filing is purely informational regarding tax treatment of a prior spin-off. Monitor for any subsequent operational updates from AnaptysBio or First Tracks.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 1 $53.14entry
- T+1 · 6mo ago −3.54%α −3.69% · $51.26
- T+5 · 5mo ago −5.21%α −2.46% · $50.37
- T+20 · 5mo ago +27.02%α +28.32% · $67.50
- T+60 · 3mo ago +9.84%α +8.61% · $58.37
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
AnaptysBio filed an 8-K under Item 7.01 to disclose that it has filed Form 8937 with the IRS regarding the tax treatment of the spin-off of First Tracks Biotherapeutics, Inc. The filing provides stockholders with information on how the dividend is treated for tax purposes and how to adjust their tax basis. This is a routine administrative disclosure with no new financial or operational information.
Key Facts
- AnaptysBio filed Form 8937 with the IRS related to the separation and spin-off of First Tracks Biotherapeutics, Inc.
- The Form 8937 provides guidance on tax treatment of the dividend and change in tax basis for stockholders.
- The information is furnished under Regulation FD and is not deemed filed for Exchange Act purposes.
Financial Impact
No financial figures disclosed; tax-basis guidance only.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-248326 |
| Document: 0001193125-26-248326-index-headers.html | 0001193125-26-248326 |
| Document: 0001193125-26-248326-index.html | 0001193125-26-248326 |
| Document: 0001193125-26-248326.txt | 0001193125-26-248326 |
Track record
28 reports on ANAB
10 of 19 bullish or bearish reports moved the stock their way by T+1. Best: +41.26% at T+60 after the Mar 3, 2026 report. 13 of 19 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $46.25 Now $45.73 −1.12% settles Nov 17
- Nov 12, 20264d ago Press Release Bearish 4/10 Entry $46.25 to $45.73 Now $45.73 +1.12% ▲ +1.12% −0.79% vs SPY
- Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Entry $46.45 to $47.97 Now $45.73 −1.55% ▲ +3.27% +0.91% vs SPY
- Sep 21, 20268w ago Press Release Neutral 5/10 Entry $53.92 to $50.77 Now $45.73 −15.19% ▼ −5.84% −5.12% vs SPY
- Aug 12, 202613w ago Institutional Cluster Bullish 5/10 Entry $56.02 to $58.47 Now $45.73 −18.37% ▲ +4.37% +4.57% vs SPY
- Jun 29, 202620w ago 144 Bearish 6/10 Entry $67.50 to $65.43 Now $45.73 +32.25% ▲ +3.07% +2.93% vs SPY
- Jun 29, 202620w ago DEFA14A Neutral 2/10 Entry $67.50 to $65.43 Now $45.73 −32.25% ▼ −3.07% −2.93% vs SPY
- Jun 26, 202620w ago 144 Bearish 6/10 Entry $65.97 to $67.50 Now $45.73 +30.68% ▼ −2.32% −1.54% vs SPY
- Jun 22, 202621w ago 8-K Neutral 2/10 Entry $59.43 to $58.48 Now $45.73 −23.05% ▼ −1.60% −1.55% vs SPY
- Jun 17, 202621w ago 144 Bearish 5/10 Entry $57.51 to $59.99 Now $45.73 +20.48% ▼ −4.31% −4.63% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers